Skip to main contentSkip to navigation
Sirius Investors

KPTI Stock: Karyopharm Therapeutics Inc. Stock Price, Analysis & Insights

Get live KPTI stock price $8.69, comprehensive Karyopharm Therapeutics Inc. stock analysis, charts, news, and expert forecast. Real-time KPTI stock data and investment insights.

8.69
2.24%Today
KPTIKaryopharm Therapeutics Inc. • NASDAQ Global Select • Healthcare
Market Cap
196.94M
Volume
323.61K
52W High
10.99
52W Low
3.65

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating...

Company Information

CEO
Richard A. Paulson
Sector
Healthcare
Industry
Biotechnology
Employees
279

Contact Information

Address
85 Wells Avenue
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Karyopharm Therapeutics Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Karyopharm Therapeutics Inc.
  • Investors should consider how Karyopharm Therapeutics Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

196.94M

P/E Ratio (TTM)

-0.53

Beta

0.82

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.